November 5, 2021
Life Sciences
  • Pfizer announced that its antiviral COVID-19 pill cut the risk of hospitalizations and deaths by 89 percent compared to those who received a placebo. The pharmaceutical company reported that three of the 389 people who received the drug (0.8 percent) were hospitalized but did not die. By comparison, there were 27 hospitalizations and seven deaths among the 385 people who received the placebo. Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the FDA as part of the emergency use application it opened in October.(Press release here; Articles here, here, here, here, here, here, and here)